AR032653A1 - Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. - Google Patents
Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.Info
- Publication number
- AR032653A1 AR032653A1 ARP020100370A ARP020100370A AR032653A1 AR 032653 A1 AR032653 A1 AR 032653A1 AR P020100370 A ARP020100370 A AR P020100370A AR P020100370 A ARP020100370 A AR P020100370A AR 032653 A1 AR032653 A1 AR 032653A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- compounds
- aryl
- transporter
- heteroaryl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 208000021642 Muscular disease Diseases 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 208000002033 Myoclonus Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008602 contraction Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provee compuestos, composiciones y métodos para inhibir al transportador de glicina 2 y para afectar la actividad neuronal mediada por el transportador de glicina. Los compuestos utiles comprenden a los compuestos de la formula (1) donde: n es 0, 1, 2 o 3 y R es independientemente, halogeno, hidroxi, alquilo inferior opcionalmente sustituido con halogeno o alcoxi menor opcionalmente sustituido con halogeno; X es O, S o N-R' (donde R' es alquilo inferior, arilo, heteroarilo, arilo-menor alquileno o heteroarilo-menor alquileno); Q puede estar ausente o presente, y cuando está presente, está representado por la formula (2) donde n, R y X son como definimos anteriormente; donde Q está presente, W es un alquileno menor y cuando Q está ausente, W está opcionalmente sustituido con alquilo inferior, opcionalmente sustituido con arilo opcionalmente sustituido con heteroarilo (opcionalmente arilo sustituido)-X-CH2- donde X es como definimos anteriormente; o su sal farmacéuticamente aceptable. Estos compuestos son particularmente utiles para tratar enfermedades nerviosas y musculares, incluyendo a la psicosis, dolor, epilepsia, enfermedades neurodegenerativas, apoplejía, trauma encefálico, esclerosis multiple y similares, y trastornos musculares, incluyendo a las enfermedades o condiciones asociadas con la contraccion aumentada del musculo, como por ejemplo, la espasticidad y mioclonus. Además, se pueden utilizar los compuestos para descubrir otros agentes con una actividad mejorada en los ensayos donde son activos los compuestos de la invencion.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26789401P | 2001-02-09 | 2001-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032653A1 true AR032653A1 (es) | 2003-11-19 |
Family
ID=23020582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100370A AR032653A1 (es) | 2001-02-09 | 2002-02-04 | Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6894054B2 (es) |
| EP (1) | EP1357913A1 (es) |
| JP (1) | JP2004522761A (es) |
| AR (1) | AR032653A1 (es) |
| AU (1) | AU2002247098B2 (es) |
| CA (1) | CA2436079A1 (es) |
| WO (1) | WO2002064135A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2842804B1 (fr) * | 2002-07-29 | 2004-09-03 | Sanofi Synthelabo | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique |
| JP2006524642A (ja) * | 2003-04-30 | 2006-11-02 | ハー・ルンドベック・アクチエゼルスカベット | 芳香族オキシフェニルおよび芳香族スルファニルフェニル誘導体 |
| WO2005044810A1 (en) * | 2003-10-30 | 2005-05-19 | Janssen Pharmaceutica, N.V. | Glyt2 modulators |
| US7563905B2 (en) * | 2004-03-12 | 2009-07-21 | Wyeth | Triazole derivatives and method of using the same to treat HIV infections |
| ES2400689T3 (es) * | 2004-10-18 | 2013-04-11 | Amgen, Inc | Compuestos de tiadiazol y métodos de uso |
| MX2007008189A (es) * | 2005-01-07 | 2007-08-07 | Hoffmann La Roche | Derivados de [4-(heteroaril)piperazin-1-il]-(fenilo 2,5-sustituido) metanona como inhibidores del transportador de glicina 1(glyt-1) para el tratamiento de trastornos neurologicos y neuropsiquiatricos. |
| AU2007207743B2 (en) * | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| AU2007310897A1 (en) * | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| WO2009011871A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| US9345703B2 (en) | 2011-09-15 | 2016-05-24 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
| CN103373993B (zh) * | 2012-04-12 | 2016-03-02 | 南京大学 | 一类含吡嗪环的噻二唑衍生物及其制法与用途 |
| CZ305680B6 (cs) * | 2013-04-04 | 2016-02-03 | Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové | Substituovaný diazol, jeho použití a farmaceutický přípravek ho obsahující |
| EP3210469A1 (de) | 2016-02-23 | 2017-08-30 | Bayer Cropscience AG | Verwendung von substituierten thio-1,2,4-triazolen zur steigerung der stresstoleranz in pflanzen |
| US12178902B1 (en) | 2020-01-12 | 2024-12-31 | University Of Southern California | Methods and compositions for fluid drainage by Piezo ion channel activation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2533604A1 (de) * | 1975-07-26 | 1977-02-10 | Bayer Ag | 2-substituierte 5-trifluormethyl1,3,4-thiadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und insektizide |
| US4325959A (en) * | 1979-08-09 | 1982-04-20 | The Dow Chemical Company | Hypoglycemic 4-(((1,3,4, thiadiazolyl)thio)methyl)benzoic acids, ester and amides |
| DE3031191A1 (de) | 1979-08-21 | 1981-03-12 | CIBA-GEIGY AG, CH 4002 Basel | 1,2,4-triazole mit pestizider wirkung |
| US4803211A (en) | 1985-07-22 | 1989-02-07 | Yamanouchi Pharmaceutical Co., Ltd. | Thiadizazole compounds as antagonists of SRS-A |
| US4900743A (en) | 1987-01-27 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | 3-aryl-5-alkylthio-4H-1,2,4-triazoles |
| DE3717865A1 (de) | 1987-05-26 | 1988-12-15 | Schering Ag | Neue 1,2,4-triazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende akarizide und insektizide mittel |
| JPH02129173A (ja) | 1988-11-10 | 1990-05-17 | Ishihara Sangyo Kaisha Ltd | トリアゾール系化合物、それらの製造方法及びそれらを含有する有害生物防除剤 |
| EP0409332A3 (en) | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
| CA2075639A1 (en) | 1990-02-13 | 1991-08-14 | William J. Greenlee | Triazole angiotensin ii antagonists incorporating a substituted benzyl element |
| JP2002514882A (ja) * | 1991-11-12 | 2002-05-21 | シナプティック・ファーマスーティカル・コーポレーション | グリシン輸送体をコードするｄｎａおよびその使用 |
| US6127131A (en) * | 1991-11-12 | 2000-10-03 | Synaptic Pharmaceutical Corporation | DNA encoding a glycine transporter and uses thereof |
| GB2263635A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
| US5240953A (en) | 1992-01-30 | 1993-08-31 | Ortho Pharmaceutical Corporation | Substituted triazoles as angiotensin ii inhibitors |
| JPH075646A (ja) | 1993-06-17 | 1995-01-10 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| AU5533394A (en) | 1993-11-12 | 1995-05-29 | Gyogyszerkutato Intezet Kft | Ulcer-inhibiting triazole derivatives, pharmaceutical compositions containing them and process for preparing same |
| US5587293A (en) * | 1994-01-06 | 1996-12-24 | Terrapin Technologies, Inc. | Method to identify binding partners |
| JPH09114055A (ja) | 1995-10-18 | 1997-05-02 | Konica Corp | ハロゲン化銀カラー写真感光材料 |
| US5670526A (en) * | 1995-12-21 | 1997-09-23 | Otsuka Pharmaceutical Co., Ltd. | 1,3,4-oxadiazoles |
| US5668159A (en) * | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
| HUP0100815A3 (en) | 1996-05-31 | 2002-11-28 | Allelix Neuroscience Inc South | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| JP4403212B2 (ja) | 1996-05-31 | 2010-01-27 | エヌピーエス ファーマシューティカルズ インコーポレイテッド | 神経障害および神経心理学的障害の治療のための製剤学的薬剤 |
| US5824486A (en) * | 1996-05-31 | 1998-10-20 | Allelix Neuroscience Inc. | Glycine transporter-transfected cells and uses thereof |
| JPH1036357A (ja) | 1996-07-25 | 1998-02-10 | Mitsubishi Kagaku Kk | トリアゾール誘導体並びにそれを含有する農園芸用殺菌剤 |
| AU5775198A (en) | 1997-01-14 | 1998-08-03 | Egis Gyogyszergyar Rt. | 2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole derivatives having an effect on the c.n.s. and the heart |
| US6008015A (en) * | 1997-04-11 | 1999-12-28 | Allelix Neuroscience Inc. | Glycine transporter |
| JP4151087B2 (ja) | 1997-07-28 | 2008-09-17 | チッソ株式会社 | スルフェニルチアジアゾール誘導体およびチアジアゾールチオエステル誘導体 |
| AU3254499A (en) | 1998-03-06 | 1999-09-20 | Janssen Pharmaceutica N.V. | Glycine transport inhibitors |
| KR20010032968A (ko) | 1998-03-06 | 2001-04-25 | 디르크 반테 | 글리신 수송 저해제 |
| GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
| JP3873746B2 (ja) | 2000-05-19 | 2007-01-24 | アステラス製薬株式会社 | トリアゾール誘導体 |
-
2002
- 2002-02-04 AR ARP020100370A patent/AR032653A1/es unknown
- 2002-02-05 US US10/072,308 patent/US6894054B2/en not_active Expired - Fee Related
- 2002-02-08 CA CA002436079A patent/CA2436079A1/en not_active Abandoned
- 2002-02-08 AU AU2002247098A patent/AU2002247098B2/en not_active Ceased
- 2002-02-08 JP JP2002563929A patent/JP2004522761A/ja not_active Withdrawn
- 2002-02-08 WO PCT/US2002/003837 patent/WO2002064135A1/en not_active Ceased
- 2002-02-08 EP EP02714858A patent/EP1357913A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1357913A1 (en) | 2003-11-05 |
| US6894054B2 (en) | 2005-05-17 |
| WO2002064135A1 (en) | 2002-08-22 |
| US20030073726A1 (en) | 2003-04-17 |
| JP2004522761A (ja) | 2004-07-29 |
| AU2002247098B2 (en) | 2006-06-22 |
| CA2436079A1 (en) | 2002-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032653A1 (es) | Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos. | |
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| RU2308454C9 (ru) | Соединения, композиции на их основе и способы их использования | |
| EA200100570A1 (ru) | Карбоновые кислоты и карбоновокислотные изостеры n-гетероциклических соединений | |
| KR960703598A (ko) | 신경 질환 치료제(agent for curing neurotic diseases) | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| EA200501332A1 (ru) | Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38 | |
| EA200400735A1 (ru) | 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ | |
| BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
| PA8431301A1 (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion | |
| RU93058531A (ru) | Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения | |
| NO20030895D0 (no) | Ny anvendelse av dipeptidyl peptidase IV inhibitorer | |
| EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
| ES2163407T3 (es) | Derivados piperidinilos tiaciclicos. | |
| EP1621195A3 (en) | The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury | |
| DE69422724D1 (de) | 1,2,4 - TRIAZOLO[1,5-a]PYRIMIDINE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN | |
| RU2009116455A (ru) | Применение индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| DE602004014791D1 (de) | Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| EA200401301A1 (ru) | Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора | |
| GT200100148A (es) | Derivados de 4-fenil-piridina. | |
| DE602004020685D1 (de) | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon | |
| WO2002079149A3 (en) | Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| WO2002079169A8 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| ES2093782T3 (es) | Piridazindionas y su uso en el tratamiento de trastornos neurologicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |